

# LIFE SAVING DRUGS PROGRAM (LSDP) EXPERT PANEL MEETING AGENDA

## 8 March 2019 MEETING

The 8 March 2019 LSDP Expert Panel Agenda consists of the following:

- 1 **Report from Chair (verbal)**
- 2 **Correspondence**
- 3 **Other Business**
- 4 **LSDP Guidance Document**
- 5 **Review of LSDP medicines matters**

Consumers will have the opportunity to provide comments on draft review items. Consumer comments can be made directly to [LSDPEP@health.gov.au](mailto:LSDPEP@health.gov.au).

<b>Item under consideration</b>	<b>Drug Name and Sponsor</b> (Drug name, trade name, sponsor)	<b>Drug Type and Use</b> (What is the drug used to treat?)	<b>Purpose of item</b>	<b>Consumer comments due</b>
Review of LSDP medicines	Imiglucerase, Cerezyme <sup>®</sup> , Genzyme Velaglucerase, VPRIV <sup>®</sup> , Shire Taliglucerase, Elelyso <sup>®</sup> , Pfizer	Enzyme replacement therapy for treatment of Gaucher disease	To agree the draft Review Protocol for the review	22 February 2019
Review of LSDP medicines	Miglustat, Zavesca <sup>®</sup> , Actelion	Oral therapy for treatment of Gaucher disease	To agree the draft Review Plan	1 March 2019
Review of LSDP medicines	Agalsidase alfa, Replagal <sup>®</sup> , Shire Agalsidase beta, Fabrazyme <sup>®</sup> , Genzyme	Enzyme replacement therapy for treatment of Fabry disease	To agree the draft Review Protocol for the review	22 February 2019
Review of LSDP medicines	Idursulfase, Elaprase <sup>®</sup> , Genzyme	Enzyme replacement therapy for treatment of Mucopolysaccharidosis Type II	To agree the draft Terms of Reference for the review	1 March 2019
Review of LSDP medicines	Alglucosidase alfa, Myozyme <sup>®</sup> , Genzyme	Enzyme replacement therapy for treatment of Pompe disease	To agree the draft Terms of Reference for the review	1 March 2019
Review of LSDP medicines	Eculizumab, Soliris <sup>®</sup> , Alexion	Therapy for Paroxysmal Nocturnal Haemoglobinuria	To agree the draft Terms of Reference for the review	1 March 2019